KOSN Kosan Biosciences presents updated data on Hsp90 inhibitor, Tanespimycin, in multiple myeloma at ASH
Briefing.com - December 10, 2007 12:16 AM ET
Related Quotes
Symbol Last Chg
KOSN Trade 3.87 -1.91
Real time quote.
Co presents updated data from a dose-escalating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin in combination with bortezomib (Velcade), showing durable antitumor activity and tolerability in patients with multiple myeloma who had previously progressed following treatment with multiple conventional therapies. The data presentation includes summary aggregate results from patients treated with all doses of Kosan's prior Cremophor-containing formulation and with Kosan's new injectable suspension formulation. Responses were seen across dose levels in the bortezomib-naive, pre-treated and refractory patients. Both formulations demonstrated activity, and the combination was manageable relative to safety, with no Grade 3 neurotoxicity to date. This finding supports the potential neuroprotective effect of tanespimycin.
ARE YOU READY????? 
